Key facts
- This page summarizes Eldon C. Mayer III's Form 4 filing for Eiger BioPharmaceuticals, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Mar 2023, 19:49.
Eldon C. Mayer III - 01 Mar 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.
- Issuer symbol
- N/A
- Report date
- 01 Mar 2023
- Net transaction value
- $0
- Form type
- 4
- Accepted by SEC
- 03 Mar 2023, 19:49:56 UTC
- Previous filing
- 30 Jan 2023
- Next filing
- 21 Mar 2023
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Eldon C. Mayer III
Source evidence
Original filing metadata and source links.
5 source fields
Reporting owner
1 detail
Key filing fact
Eldon C. Mayer III filed Form 4 for Eiger BioPharmaceuticals, Inc. on 03 Mar 2023.
Change
- Previous filing in this sequence was filed on 30 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EIGR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +98,000
- Change %
- Price
- $0.000000
- Shares after
- 98,000
- Date
- 01 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 98,000
- Exercise price
- $1.70
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
. The option vests in 48 equal monthly installments commencing on the grant date of March 1, 2023, subject to the Reporting Person's continuous service as of such date.